CustomVue offers good results in mixed astigmatism

Article

Excellent visual outcomes can be achieved in subjects with mixed astigmatism when using the VISX wavefront platform's CustomVue iris registration system (AMO).

Excellent visual outcomes can be achieved in subjects with mixed astigmatism when using the VISX wavefront platform's CustomVue iris registration system (AMO), according to Baha Toygar and co-workers from the Dunya Eye Hospital, Istanbul, Turkey.

Sixteen eyes with mixed astigmatism were enrolled into the prospective study in which all LASIK procedures were performed by the same surgeon.

Three months following surgery, mean astigmatism had reduced from -3.14±1.06 D to -0.33±0.44 D. The majority of eyes (81%) had less than -0.50 D residual astigmatism and 87.5% had less than -1.0 D. Mean uncorrected and best corrected visual acuity (UCVA & BCVA) improved from 0.24±0.13 to 0.79±0.27 and from 0.84±0.20 to 0.95±0.11, respectively.

Overall, these results demonstrate that the VISX wavefront platform's CustomVue iris registration system can offer excellent visual outcomes for subjects with mixed astigmatism.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.